Akbari A, Sriperumbuduri S, Mangalgi S, Joshi V, Sood M, Buh A
Kidney Med. 2025; 7(3):100965.
PMID: 39980937
PMC: 11840182.
DOI: 10.1016/j.xkme.2025.100965.
Stanajic-Petrovic G, Keck M, Barbe P, Urman A, Correia E, Isnard P
J Am Soc Nephrol. 2024; 36(2):181-192.
PMID: 39431458
PMC: 11801765.
DOI: 10.1681/ASN.0000000505.
Jaturanratsamee K, Jiwaganont P, Sukumolanan P, Petchdee S
F1000Res. 2024; 12:760.
PMID: 39108347
PMC: 11301141.
DOI: 10.12688/f1000research.134906.2.
Liu H, Zhong H, Zhang Y, Xue H, Zhang Z, Fu K
Acta Pharmacol Sin. 2024; 45(11):2441-2449.
PMID: 38902502
PMC: 11489814.
DOI: 10.1038/s41401-024-01325-5.
Gobburu J, Ivaturi V, Wang X, Shoaf S, Jadhav P, Perrone R
Kidney360. 2023; 4(12):1702-1707.
PMID: 37986188
PMC: 10758521.
DOI: 10.34067/KID.0000000000000302.
Copeptin in autosomal dominant polycystic kidney disease: real-world experiences from a large prospective cohort study.
Arjune S, Oehm S, Todorova P, Gansevoort R, Bakker S, Erger F
Clin Kidney J. 2023; 16(11):2194-2204.
PMID: 37915893
PMC: 10616446.
DOI: 10.1093/ckj/sfad118.
Compartmentalised cAMP signalling in the primary cilium.
Paolocci E, Zaccolo M
Front Physiol. 2023; 14:1187134.
PMID: 37256063
PMC: 10226274.
DOI: 10.3389/fphys.2023.1187134.
Natural-derived compounds and their mechanisms in potential autosomal dominant polycystic kidney disease (ADPKD) treatment.
Mahendran R, Lim S, Ong K, Chua K, Chai H
Clin Exp Nephrol. 2021; 25(11):1163-1172.
PMID: 34254206
DOI: 10.1007/s10157-021-02111-x.
The Biology of Vasopressin.
Sparapani S, Millet-Boureima C, Oliver J, Mu K, Hadavi P, Kalostian T
Biomedicines. 2021; 9(1).
PMID: 33477721
PMC: 7832310.
DOI: 10.3390/biomedicines9010089.
Targeting and therapeutic peptide-based strategies for polycystic kidney disease.
Wang J, Tripathy N, Chung E
Adv Drug Deliv Rev. 2020; 161-162:176-189.
PMID: 32866560
PMC: 7736157.
DOI: 10.1016/j.addr.2020.08.011.
Metabolic Changes in Polycystic Kidney Disease as a Potential Target for Systemic Treatment.
Haumann S, Muller R, Liebau M
Int J Mol Sci. 2020; 21(17).
PMID: 32847032
PMC: 7503958.
DOI: 10.3390/ijms21176093.
Auxiliary genetic analysis in a Chinese adolescent NPH family by single nucleotide polymorphism screening.
Tang C, Zhou D, Tan R, Zhong X, Xiao X, Qin D
Mol Med Rep. 2020; 21(3):1115-1124.
PMID: 31922211
PMC: 7003018.
DOI: 10.3892/mmr.2020.10917.
Vasopressin Increases Urinary Acidification V1a Receptors in Collecting Duct Intercalated Cells.
Giesecke T, Himmerkus N, Leipziger J, Bleich M, Koshimizu T, Fahling M
J Am Soc Nephrol. 2019; 30(6):946-961.
PMID: 31097611
PMC: 6551786.
DOI: 10.1681/ASN.2018080816.
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Gansevoort R, van Gastel M, Chapman A, Blais J, Czerwiec F, Higashihara E
Kidney Int. 2019; 96(1):159-169.
PMID: 30898339
PMC: 6640141.
DOI: 10.1016/j.kint.2018.11.044.
Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort.
McKenzie K, El Ters M, Torres V, Harris P, Chapman A, Mrug M
BMC Nephrol. 2018; 19(1):378.
PMID: 30591038
PMC: 6307167.
DOI: 10.1186/s12882-018-1182-0.
N-Degradomic Analysis Reveals a Proteolytic Network Processing the Podocyte Cytoskeleton.
Rinschen M, Hoppe A, Grahammer F, Kann M, Volker L, Schurek E
J Am Soc Nephrol. 2017; 28(10):2867-2878.
PMID: 28724775
PMC: 5619959.
DOI: 10.1681/ASN.2016101119.
Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?.
Janssens P, Weydert C, De Rechter S, Wissing K, Liebau M, Mekahli D
Pediatr Nephrol. 2017; 33(3):395-408.
PMID: 28455745
DOI: 10.1007/s00467-017-3672-x.
New Insights into the Molecular Mechanisms Targeting Tubular Channels/Transporters in PKD Development.
Wu M, Yu S
Kidney Dis (Basel). 2016; 2(3):128-135.
PMID: 27921040
PMC: 5123004.
DOI: 10.1159/000444839.
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
Devuyst O, Chapman A, Gansevoort R, Higashihara E, Perrone R, Torres V
J Am Soc Nephrol. 2016; 28(5):1592-1602.
PMID: 27920153
PMC: 5407721.
DOI: 10.1681/ASN.2016040448.
Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR/Cas9 technology.
Pereira E, Labilloy A, Eshbach M, Roy A, Subramanya A, Monte S
Am J Physiol Renal Physiol. 2016; 311(5):F1015-F1024.
PMID: 27681560
PMC: 5130460.
DOI: 10.1152/ajprenal.00283.2016.